ReWalk Robotics (NASDAQ:LFWD) Price Target Increased to $13.00 by Analysts at HC Wainwright

ReWalk Robotics (NASDAQ:LFWD) had its price target upped by HC Wainwright from $9.00 to $13.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Lake Street Capital raised ReWalk Robotics to a strong-buy rating in a research report on Monday, June 24th.

ReWalk Robotics Stock Down 0.5 %

ReWalk Robotics stock opened at $3.70 on Friday. The company has a market capitalization of $32.26 million, a P/E ratio of -1.19 and a beta of 2.06. The stock’s 50 day moving average is $3.96 and its 200 day moving average is $4.83. ReWalk Robotics has a twelve month low of $3.00 and a twelve month high of $9.10.

ReWalk Robotics (NASDAQ:LFWD) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The business had revenue of $6.71 million for the quarter, compared to analysts’ expectations of $6.71 million. ReWalk Robotics had a negative return on equity of 39.72% and a negative net margin of 102.03%. During the same period in the prior year, the firm posted ($0.35) EPS. As a group, equities analysts expect that ReWalk Robotics will post -1.94 EPS for the current year.

Institutional Investors Weigh In On ReWalk Robotics

An institutional investor recently bought a new position in ReWalk Robotics stock. Kent Lake Capital LLC acquired a new stake in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 157,361 shares of the company’s stock, valued at approximately $823,000. Kent Lake Capital LLC owned approximately 1.85% of ReWalk Robotics as of its most recent SEC filing. Institutional investors own 26.76% of the company’s stock.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.